ClinicalTrials.gg
CompletedNCT00851903Updated Oct 4, 2012Results posted

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

A Phase 3 interventional study of Insulin Glargine and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 16 sites in 16 countries. Open to participants aged 35 Years to 71 Years. Per ClinicalTrials.gov, last updated 2012-10-04.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
35 Years to 71 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
118th of 175
112 · median 253
Started
2009
with 9 others
Phase 3
60 of 176
1 open now
Registered
61st of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 118th largest by enrollment of the 175 interventional ones that give a count, is one of 10 that started in 2009, is one of 60 in phase 3, and was the 61st registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 71 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study was the extension of the LANTU_C_02761 study named EASIE and identified as NCT00751114 (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately controlled).

All patients with Glycosylated Hemoglobin A1c (HbA1c) ≥ 7% at the end of the core study had the possibility to enter this extension study if they met the other inclusion criteria and did not present with any exclusion criteria.

The visit 14 of the core study (week 24) was the visit 1 (baseline, week 0) of the extension study which consisted of a 12-week treatment period.

The objectives of this extension study were:

  • To assess the glycemic control (HbA1c \<7%) of a 3-month combination therapy with metformin, insulin glargine and sitagliptin in patients not adequately controlled by a previous treatment with metformin plus either insulin glargine or sitagliptin.
  • To assess the effect of insulin glargine in combination with sitagliptin on HbA1c level, fasting plasma glucose, 7-point glucose profile, hypoglycemia occurrence, body weight and overall safety.
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
35 Years to 71 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed the core study LANTU_C_02761 (NCT00751114) i.e. went through the visit 14 investigation,
  • >= 7 %,
  • Dose of metformin compliant with the inclusion criteria of the core study (i.e. at least 1 g/day), and maintained stable for the duration of the core study
  • Ability and willingness to perform plasma blood glucose monitoring using the sponsor-provided plasma glucose meter and to complete the patient dairy,
  • Signed obtained prior any study procedure,
  • Willingness and ability to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Treatment with oral antidiabetic drugs other than metformin and sitagliptin in the core study,
  • Treatment with insulin other than Insulin Glargine in the core study (except in case of an emergency, for a period of time less than 7 days),
  • Treatment with a non-permitted drug during the core study,
  • Pregnant or lactating women,
  • In-patient care,
  • Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study (an optic fundus examination should have been performed within the 2 years prior to study entry in the core study),
  • Impaired renal function: serum creatinine >= 1.5 mg/dL (>= 133µmol/L) or >= 1.4 mg/dL (>=124 µmol/L) in men and women, respectively,
  • History of sensitivity to the study drugs or to drugs with a similar chemical structure,
  • Impaired hepatic function: (ALT), aspartate aminotransferase (AST) > 3 x ,
  • Alcohol or drug abuse within the last year,
  • Night shift worker,
  • Presence of any condition (medical, psychological, social or geographical), current or anticipated that the investigator feels would compromise the patient's safety or limit the patient successful participation in the study,
  • Treatment with weight loss medications (e.g. sibutramine, orlistat, rimonabant),
  • History of pancreatitis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Combination insulin glargine and sitagliptin

    Insulin glargine administered once a day, in the evening, at dinner or at bedtime. Starting dose: - last dose administered in the core study for patients previously treated with insulin glargine, - 0.2 U/Kg of body weight for patients previously treated with sitagliptin. Monitoring of blood glucose and titration: all patients, irrespective of their previous treatment group in the core study were empowered to adjust their insulin doses, under strict investigator's supervision. The goal was to achieve through a force titration 70 \< Fasting Plasma Glucose (FPG) ≤ 100 mg/dL (3.9 \<FPG ≤ 5.5 mmol/L). Sitagliptin: stable dose of 100 mg once a day administered with or without food.

    Drug: Insulin Glargine · Drug: Sitagliptin · Drug: Metformin

Interventions

  • Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).

    Also known as: Lantus®

  • Oral administration. 100mg film-coated tablets.

    Also known as: Januvia®

  • Patients continued with metformin as usual oral anti-diabetic treatment.

06

What researchers measure

Primary outcomes

  1. HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period)

    Time frame: study endpoint: week 12 or earlier in case of premature discontinuation

Secondary outcomes

  1. HbA1c: Change From Baseline to Study Endpoint

    Change = study endpoint - baseline

    Time frame: baseline, study endpoint: week 12 or earlier in case of premature discontinuation

  2. Self-Monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint

    SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed). Change = study endpoint - baseline.

    Time frame: baseline, study endpoint: week 12 or week 8 if value not available at week 12

  3. 7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint

    7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime. Change = study endpoint - baseline.

    Time frame: baseline, study endpoint: week 12 or week 8 if value not available at week 12

  4. Insulin Dose

    Daily dose at the face-to-face visits

    Time frame: baseline, week 4, week 8, week 12

  5. Number of Patients With at Least One Episode of Symptomatic Hypoglycemia

    Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement \<= 70mg/dL \[3.9 mmol/L\]

    Time frame: During the treatment period (12 weeks) plus 7 days after last dose

  6. Change in Body Weight From Baseline to Study Endpoint

    Change = study endpoint - baseline

    Time frame: baseline, study endpoint: week 12 or week 8 or week 4 depending on last available value

07

Results

Posted Oct 4, 2012

Participant flow

Among the 445 patients who completed the EASIE study, 194 had an endpoint Glycosylated Hemoglobin A1c (HbA1c) ≥ 7%. A total of 112 patients were included in the extension study: 37 uncontrolled on previous treatment with metformin and insulin glargine and 75 uncontrolled on previous treatment with metformin and sitagliptin in the EASIE study.

Participant flow — Overall Study
MilestoneCombination Insulin Glargine and Sitagliptin
Started112
Safety population112
Treated by combination111
Modified intent-to-treat population111
Completed110
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryHbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period)
Time frame:
study endpoint: week 12 or earlier in case of premature discontinuation
Reported as:
Number · percentage of participants
HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period)
percentage of participantsCombination Insulin Glargine and Sitagliptin
HbA1c Response Rate: Percentage of Patients Achieving Glycosylated Haemoglobin A1c (HbA1c) < 7% at Study Endpoint (End of Treatment Period)51.9 (41.97 to 61.70)
SecondaryHbA1c: Change From Baseline to Study Endpoint

Change = study endpoint - baseline

Time frame:
baseline, study endpoint: week 12 or earlier in case of premature discontinuation
Reported as:
Mean · percent
HbA1c: Change From Baseline to Study Endpoint
percentCombination Insulin Glargine and Sitagliptin
HbA1c: Change From Baseline to Study Endpoint-0.80 ± 1.05
SecondarySelf-Monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint

SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed). Change = study endpoint - baseline.

Time frame:
baseline, study endpoint: week 12 or week 8 if value not available at week 12
Reported as:
Mean · mg/dL
Self-Monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint
mg/dLCombination Insulin Glargine and Sitagliptin
Self-Monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint-35.43 ± 39.61
Secondary7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint

7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime. Change = study endpoint - baseline.

Time frame:
baseline, study endpoint: week 12 or week 8 if value not available at week 12
Reported as:
Mean · mg/dL
7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint
mg/dLCombination Insulin Glargine and Sitagliptin
Before breakfast (N=104)-34.2 ± 38.1
After breakfast (N=103)-34.1 ± 48.1
Before lunch (N=104)-26.6 ± 48.2
After lunch (N=104)-26.5 ± 43.7
Before dinner (N=103)-25.1 ± 43.0
After dinner (N=100)-24.9 ± 46.7
At bedtime (N=93)-35.2 ± 51.7
SecondaryInsulin Dose

Daily dose at the face-to-face visits

Time frame:
baseline, week 4, week 8, week 12
Reported as:
Mean · unit per kg body weight
Insulin Dose
unit per kg body weightCombination Insulin Glargine and Sitagliptin
Baseline0.28 ± 0.18
Week 4 N=1100.37 ± 0.16
Week 8 N=1100.42 ± 0.18
Week 120.46 ± 0.20
SecondaryNumber of Patients With at Least One Episode of Symptomatic Hypoglycemia

Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement \<= 70mg/dL \[3.9 mmol/L\]

Time frame:
During the treatment period (12 weeks) plus 7 days after last dose
Reported as:
Number · participants
Number of Patients With at Least One Episode of Symptomatic Hypoglycemia
participantsCombination Insulin Glargine and Sitagliptin
Number of Patients With at Least One Episode of Symptomatic Hypoglycemia40
SecondaryChange in Body Weight From Baseline to Study Endpoint

Change = study endpoint - baseline

Time frame:
baseline, study endpoint: week 12 or week 8 or week 4 depending on last available value
Reported as:
Mean · kg
Change in Body Weight From Baseline to Study Endpoint
kgCombination Insulin Glargine and Sitagliptin
Change in Body Weight From Baseline to Study Endpoint1.15 ± 2.24

Adverse events

Collected over Adverse events were assessed throughout the extension study (12 weeks). Only adverse events starting from inclusion in the extension study were taken into account.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination Insulin Glargine and Sitagliptin—2/112 (1.8%)0/112 (0%)
Most frequent serious events
Most frequent serious events
EventCombination Insulin Glargine and Sitagliptin
Right ventricular failureCardiac disorders1/112
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/112

Baseline characteristics

Age Continuous
Age Continuous(years)Combination Insulin Glargine and Sitagliptin
Mean52.4 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Combination Insulin Glargine and Sitagliptin
Female56
Male55
Body Weight
Body Weight(kg)Combination Insulin Glargine and Sitagliptin
Mean84.6 ± 21.0
Body Mass Index
Body Mass Index(kg/m²)Combination Insulin Glargine and Sitagliptin
Mean31.3 ± 5.2
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)Combination Insulin Glargine and Sitagliptin
Mean129.9 ± 15.5
Diastolic Blood Pressure
Diastolic Blood Pressure(mmHg)Combination Insulin Glargine and Sitagliptin
Mean80.1 ± 7.3
Heart Rate
Heart Rate(beats/min)Combination Insulin Glargine and Sitagliptin
Mean76.9 ± 9.1
Duration of diabetes
Duration of diabetes(years)Combination Insulin Glargine and Sitagliptin
Median4.1 ± 5.1

4 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Bogota, Colombia
  • Sanofi-Aventis Administrative Office
    Cairo, Egypt
  • Sanofi-Aventis Administrative Office
    Kallithea, Greece
  • Sanofi-Aventis Administrative Office
    Hong Kong, Hong Kong
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    Beirut, Lebanon
  • Sanofi-Aventis Administrative Office
    Col. Coyoacan, Mexico
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2009
First posted
Feb 26, 2009
Start
Jun 2009
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Oct 4, 2012
Last update
Oct 4, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00851903
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 26, 2009
Start date
Jun 2009
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Oct 4, 2012
Last update
Oct 4, 2012

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Sitagliptin · Metformin

Start the discussion